Statements (59)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:healthcare_organization
|
gptkbp:bfsLayer |
3
|
gptkbp:bfsParent |
gptkb:Insurance_Company
|
gptkbp:affects |
neuromuscular junction
|
gptkbp:associated_with |
small cell lung cancer
thymoma other malignancies |
gptkbp:caused_by |
autoimmune response
|
gptkbp:clinical_trial |
ongoing studies
autonomic dysfunction reflexes may be diminished proximal muscle weakness muscle strength may improve with repeated use |
gptkbp:current_use |
gptkb:Insurance_Company
|
gptkbp:demographics |
more common in men
|
gptkbp:first_described_by |
Eaton and Lambert
|
https://www.w3.org/2000/01/rdf-schema#label |
lambert-eaton syndrome
|
gptkbp:is_a_route_for |
antibodies against voltage-gated calcium channels
|
gptkbp:is_popular_in |
rare
|
gptkbp:premiered_on |
typically between 40 and 60
can occur in adults |
gptkbp:research_areas |
neurology
oncology immunology |
gptkbp:research_focus |
patient registries
treatment efficacy genetic predisposition environmental triggers quality of life assessments long-term outcomes biomarkers for diagnosis immunological markers understanding autoimmune mechanisms |
gptkbp:social_responsibility |
variable
electromyography blood tests for antibodies |
gptkbp:symptoms |
fatigue
muscle weakness difficulty breathing difficulty swallowing dry mouth muscle cramps impaired vision improvement with exercise |
gptkbp:treatment |
gptkb:mycophenolate_mofetil
gptkb:methotrexate gptkb:physicist gptkb:vaccine gptkb:cyclophosphamide gptkb:rituximab gptkb:azathioprine physical therapy supportive care monoclonal antibodies symptomatic treatment plasma exchange immunosuppressive drugs acetylcholinesterase inhibitors IVIG |